Floatz Rating
B60/100
Confidence
Indicative
Sponsor
St. Jude Children's Research Hospital
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07616154CT.gov Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease | — | Not Yet Recruiting | — | — | — |
NCT07599176CT.gov Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors | — | Recruiting | — | — | — |
NCT06872333CT.gov Allo HSCT for High Risk Hemoglobinopathies | — | Recruiting | — | — | — |
NCT06358638CT.gov Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody | — | Recruiting | — | — | — |
NCT06145282CT.gov Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function | — | Active Not Recruiting | — | — | — |
NCT05905770CT.gov Do Alemtuzumab Levels Predict T Cell Chimerism After MSD SCT for SCD? | — | Unknown | — | — | — |
NCT05384756CT.gov TMLI and Alemtuzumab for Treatment of Sickle Cell Disease | — | Active Not Recruiting | — | — | — |
NCT05357482CT.gov Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia | — | Active Not Recruiting | — | — | — |
NCT04362293CT.gov Reduced Intensity Transplantation for Severe Sickle Cell Disease | — | Suspended | — | — | — |
NCT03653338CT.gov T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias | — | Recruiting | — | — | — |
Show 19 more trialsShow fewer
NCT03587272CT.gov Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease | — | Recruiting | — | — | — |
NCT03421756CT.gov Stem Cell Transplant in Patients With Severe Sickle Cell Disease | — | Terminated | — | — | — |
NCT03279094CT.gov Haploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease | — | Recruiting | — | — | — |
NCT03214354CT.gov Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor | — | Recruiting | — | — | — |
NCT03077542CT.gov Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease | — | Active Not Recruiting | — | — | — |
NCT03128996CT.gov Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders | — | Recruiting | — | — | — |
NCT02766465CT.gov Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503) | — | Completed | — | — | — |
NCT02867800CT.gov Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease | — | Completed | — | — | — |
NCT02678143CT.gov Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease | — | Terminated | — | — | — |
NCT02105766CT.gov Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure | — | Active Not Recruiting | — | — | — |
NCT02013375CT.gov SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD | — | Terminated | — | — | — |
NCT01499888CT.gov Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD) | — | Active Not Recruiting | — | — | — |
NCT01049854CT.gov CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant | — | Completed | — | — | — |
NCT00977691CT.gov Haploidentical PBMC Transplant for Severe Congenital Anemias | — | Active Not Recruiting | — | — | — |
NCT02435901CT.gov HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity | — | Completed | — | — | — |
NCT00745420CT.gov Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601) | — | Completed | — | — | — |
NCT00152113CT.gov Haploidentical Stem Cell Transplant for Patients With Sickle Cell Disease and Prior Stroke or Abnormal Transcranial Ultrasound | — | Completed | — | — | — |
NCT00061568CT.gov Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias | — | Unknown | — | — | — |
NCT00029393CT.gov Induction of Stable Chimerism for Sickle Cell Anemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Sickle Cell Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Alemtuzumab (this asset) | St. Jude Children's Research Hospital | P3 | B · 60 |
| Glutamine | Ain Shams University | P4 | BBB |
| Hydroxyurea | St. Jude Children's Research Hospital | P4 | BB |
| Magnesium Metallicum | Medical College of Wisconsin | P3 | BB |
| Nivestim | St. Jude Children's Research Hospital | P4 | BB |
| Crizanlizumab | Novartis Pharmaceuticals | P4 | BB |
| Fentanyl | University College Dublin | P4 | BB |
| Nepenthe | Oman Medical Speciality Board | P4 | BB |
| ARG | Tanta University | P3 | BB |
+42 more in the Sickle Cell Disease cohort
Other indications for Alemtuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Relapsing-Remitting Multiple Sclerosis | — | P4 | BBB · 73 |
| Myelodysplastic/Myeloproliferative Neoplasm | — | P2 | BB · 71 |
| Chronic Myeloid Leukemia | — | P2/3 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Alemtuzumab in Sickle Cell Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-human-rat-monoclonal-campath-1h-gamma1-chain-anti-human-antigen-cd52-disulfide-with-human-rat-monoclonal-campath-1h-light-chain-dimer-sickle-cell-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →